Art

J-GLOBAL ID：200902253678789507   Reference number：07A1026741

Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors

Chk1キナーゼ阻害剤のピラゾロキノリノン部類の最適化

Author (25)： BRNARDIC Edward J. (Dep. of Medicinal Chemistry, Merck Res. Laboratories, West Point, PA 19486, USA) ,  GARBACCIO Robert M. (Dep. of Medicinal Chemistry, Merck Res. Laboratories, West Point, PA 19486, USA) ,  FRALEY Mark E. (Dep. of Medicinal Chemistry, Merck Res. Laboratories, West Point, PA 19486, USA) ,  TASBER Edward S. (Dep. of Medicinal Chemistry, Merck Res. Laboratories, West Point, PA 19486, USA) ,  STEEN Justin T. (Dep. of Medicinal Chemistry, Merck Res. Laboratories, West Point, PA 19486, USA) ,  ARRINGTON Kenneth L. (Dep. of Medicinal Chemistry, Merck Res. Laboratories, West Point, PA 19486, USA) ,  DUDKIN Vadim Y. (Dep. of Medicinal Chemistry, Merck Res. Laboratories, West Point, PA 19486, USA) ,  HARTMAN George D. (Dep. of Medicinal Chemistry, Merck Res. Laboratories, West Point, PA 19486, USA) ,  STIRDIVANT Steven M. (Dep. of Cancer Res., Merck Res. Laboratories, West Point, PA 19486, USA) ,  DRAKAS Bob A. (Dep. of Cancer Res., Merck Res. Laboratories, West Point, PA 19486, USA) ,  RICKERT Keith (Dep. of Cancer Res., Merck Res. Laboratories, West Point, PA 19486, USA) ,  WALSH Eileen S. (Dep. of Cancer Res., Merck Res. Laboratories, West Point, PA 19486, USA) ,  HAMILTON Kelly (Dep. of Cancer Res., Merck Res. Laboratories, West Point, PA 19486, USA) ,  BUSER Carolyn A. (Dep. of Cancer Res., Merck Res. Laboratories, West Point, PA 19486, USA) ,  HARDWICK James (Dep. of Cancer Res., Merck Res. Laboratories, West Point, PA 19486, USA) ,  TAO Weikang (Dep. of Cancer Res., Merck Res. Laboratories, West Point, PA 19486, USA) ,  BECK Stephen C. (Dep. of Cancer Res., Merck Res. Laboratories, West Point, PA 19486, USA) ,  MAO Xianzhi (Dep. of Cancer Res., Merck Res. Laboratories, West Point, PA 19486, USA) ,  LOBELL Robert B. (Dep. of Cancer Res., Merck Res. Laboratories, West Point, PA 19486, USA) ,  SEPP-LORENZINO Laura (Dep. of Cancer Res., Merck Res. Laboratories, West Point, PA 19486, USA) ,  YAN Youwei (Dep. of Structural Biology, Merck Res. Laboratories, West Point, PA 19486, USA) ,  IKUTA Mari (Dep. of Structural Biology, Merck Res. Laboratories, West Point, PA 19486, USA) ,  MUNSHI Sanjeev K. (Dep. of Structural Biology, Merck Res. Laboratories, West Point, PA 19486, USA) ,  KUO Lawrence C. (Dep. of Structural Biology, Merck Res. Laboratories, West Point, PA 19486, USA) ,  KREATSOULAS Constantine (Dep. of Molecular Systems, Merck Res. Laboratories, West Point, PA 19486, USA)
Material： Bioorganic & Medicinal Chemistry Letters  (Bioorg Med Chem Lett)
Volume： 17  Issue： 21  Page： 5989-5994  Publication year： Nov. 01, 2007 
JST Material Number： W0248A  ISSN： 0960-894X  Document type： Article
Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Terms in the title (4)： Chk1 ,  キナーゼ阻害剤 ,  部類 ,  最適化